Seven Fleet Capital Management LP Takes Position in Evolus, Inc. $EOLS

Seven Fleet Capital Management LP purchased a new position in shares of Evolus, Inc. (NASDAQ:EOLS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 82,000 shares of the company’s stock, valued at approximately $545,000. Seven Fleet Capital Management LP owned 0.13% of Evolus as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in EOLS. Alpine Global Management LLC acquired a new stake in Evolus in the fourth quarter valued at about $173,000. Virtu Financial LLC purchased a new position in shares of Evolus during the 4th quarter worth approximately $151,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Evolus in the 4th quarter valued at approximately $144,000. Wellington Management Group LLP lifted its holdings in shares of Evolus by 5.9% in the 4th quarter. Wellington Management Group LLP now owns 195,160 shares of the company’s stock valued at $1,298,000 after buying an additional 10,850 shares during the period. Finally, Quadrature Capital Ltd boosted its stake in shares of Evolus by 29.9% in the fourth quarter. Quadrature Capital Ltd now owns 18,095 shares of the company’s stock valued at $120,000 after buying an additional 4,168 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on EOLS. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. BTIG Research restated a “buy” rating and set a $13.00 target price on shares of Evolus in a research report on Wednesday. Finally, Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Evolus presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Evolus Trading Down 1.6%

EOLS stock opened at $6.63 on Friday. The firm has a 50 day moving average of $5.92 and a 200-day moving average of $5.54. The company has a market cap of $436.65 million, a price-to-earnings ratio of -9.90 and a beta of 1.34. Evolus, Inc. has a 12-month low of $3.86 and a 12-month high of $10.20.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million. During the same quarter in the prior year, the company posted ($0.30) EPS. Sell-side analysts forecast that Evolus, Inc. will post -0.38 earnings per share for the current fiscal year.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.